RxSight, Inc.

Equities

RXST

US78349D1072

Medical Equipment, Supplies & Distribution

Real-time Estimate Cboe BZX Other stock markets 10:04:32 2024-04-29 am EDT			5-day change	1st Jan Change
52.88 ^USD	+0.22%		+1.95%	+32.34%

Apr. 04	RxSight Launches New Light Adjustable Lens Product	MT
Apr. 04	RxSight, Inc. Announces Commercial Launch of its Newest Light Adjustable Lens??, the LAL+??, and Features Multiple Doctor Presentations at the Upcoming ASCRS Annual Meeting	CI

RxSight, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023

February 28, 2024 at 04:05 pm EST

RxSight, Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported sales was USD 28.58 million compared to USD 16.09 million a year ago. Net loss was USD 9.18 million compared to USD 15.61 million a year ago.

Basic loss per share from continuing operations was USD 0.26 compared to USD 0.56 a year ago.

Latest news about RxSight, Inc.

RxSight Launches New Light Adjustable Lens Product	Apr. 04	MT
RxSight, Inc. Announces Commercial Launch of its Newest Light Adjustable Lens??, the LAL+??, and Features Multiple Doctor Presentations at the Upcoming ASCRS Annual Meeting	Apr. 04	CI
Rxsight Insider Sold Shares Worth $997,946, According to a Recent SEC Filing	Apr. 02	MT
Needham Raises Price Target on RxSight to $64 From $53, Maintains Buy Rating	Feb. 29	MT
Oppenheimer Adjusts RxSight Price Target to $61 From $54, Maintains Outperform Rating	Feb. 29	MT
RxSight's Q4 Adjusted Loss Narrows, Sales Increase; Reiterates 2024 Revenue Guidance	Feb. 29	MT
Transcript : RxSight, Inc., Q4 2023 Earnings Call, Feb 28, 2024	Feb. 28
Earnings Flash (RXST) RXSIGHT Reports Q4 Revenue $28.6M, vs. Street Est of $27.9M	Feb. 28	MT
Rxsight, Inc. Reiterates Earnings Guidance for the Full Year 2024	Feb. 28	CI
RxSight, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
RxSight, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 28	CI
Rxsight Insider Sold Shares Worth $1,350,000, According to a Recent SEC Filing	Feb. 16	MT
Rxsight Insider Bought Shares Worth $406,673, According to a Recent SEC Filing	Feb. 15	MT
RxSight Insider Sold Shares Worth $525,939, According to a Recent SEC Filing	Feb. 13	MT
Stifel Adjusts Price Target on RxSight to $54 From $45, Maintains Buy Rating	Feb. 12	MT
Rxsight Insider Sold Shares Worth $1,182,660, According to a Recent SEC Filing	Feb. 07	MT
Rxsight Insider Sold Shares Worth $500,004, According to a Recent SEC Filing	Feb. 02	MT
Rxsight Insider Sold Shares Worth $351,411, According to a Recent SEC Filing	Feb. 02	MT
Rxsight Insider Sold Shares Worth $1,403,120, According to a Recent SEC Filing	Feb. 02	MT
Rxsight Insider Sold Shares Worth $1,496,706, According to a Recent SEC Filing	Jan. 29	MT
Oppenheimer Raises RxSight Price Target to $54 From $50, Maintains Outperform Rating	Jan. 29	MT
RxSight Insider Sold Shares Worth $480,006, According to a Recent SEC Filing	Jan. 23	MT
Rxsight Insider Sold Shares Worth $292,555, According to a Recent SEC Filing	Jan. 19	MT
Oppenheimer Raises RxSight Price Target to $50 From $46, Maintains Outperform Rating	Jan. 16	MT
Transcript : RxSight, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 03:00 PM	Jan. 10

Chart RxSight, Inc.

Duration

Period

More charts

Company Profile

RxSight, Inc. is a commercial-stage medical technology company, which is engaged in improving the vision of patients following cataract surgery. The Companyâs RxSight Light Adjustable Lens system (RxSight system) is a cataract technology that enables doctors to customize and optimize visual acuity for patients after surgery. The RxSight system includes the RxSight Light Adjustable Lens (LAL), the RxSight Light Delivery Device (LDD), and various accessories. Its LAL is an intraocular lens (IOL) made of photosensitive material that changes shape in response to specific patterns of ultraviolet (UV) light generated by its LDD. It designed its RxSight system to address the shortcomings of competitive IOL technologies and provide a solution that doctors can trust to improve visual outcomes. Its RxSight system helps the surgeon perform a standard cataract procedure to implant the LAL and then uses the LDD to modify the lens with the visual correction needed for the patientâs vision outcomes.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-05-06 - Q1 2024 Earnings Release

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for RxSight, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

52.77 USD

Average target price

62.62 USD

Spread / Average Target

+18.68%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
RXSIGHT, INC.	+32.34%	1.96B
ABBOTT LABORATORIES	-1.93%	187B
MEDTRONIC PLC	-2.58%	106B
BECTON, DICKINSON AND COMPANY	-4.11%	66.9B
DEXCOM, INC.	+2.79%	49.45B
CENCORA, INC.	+16.74%	48B
HOYA CORPORATION	+4.06%	40.84B
METTLER-TOLEDO INTERNATIONAL, INC.	+3.10%	26.48B
WEST PHARMACEUTICAL SERVICES, INC.	+2.15%	26.25B
TERUMO CORPORATION	+12.96%	24.62B

Other Medical Equipment, Supplies & Distribution